People living with multidrug-resistant (MDR) HIV-1 need options
it's time for RUKOBIA
A first-in-class attachment inhibitor that directly targets HIV-1
to protect CD4+ T-cells 1,2*
People living with multidrug-
resistant (MDR) HIV-1 need
options
it's time for RUKOBIA
A first-in-class attachment
inhibitor that directly targets
HIV-1 to protect CD4+ T-cells 1,2*
INDICATION
RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.
*Prevents HIV-1 from interacting with host immune cells by binding gp120, leaving CD4+ T-cells untouched.
HIV-1=human immunodeficiency virus type-1; gp120=glycoprotein 120.
Sign Up for our next webinar
Listen to Edge of Yesterday:
A Podcast Series by ViiV Healthcare
DISCOVER RUKOBIA
BRIGHTE CLINICAL TRIAL
Learn about the efficacy and safety of RUKOBIA in BRIGHTE
DOSING AND DRUG INTERACTIONS
Learn about administering RUKOBIA
ViiV MEDICAL INFORMATION
View our medical information library if you have a question about RUKOBIA
A DEEPER LOOK AT RUKOBIA
RISKS & SIDE EFFECTS
Get information about the possible risks and side effects, including warnings and precautions and rates of discontinuation
A NOVEL
MECHANISM
OF ACTION
Learn what makes RUKOBIA a first-in-class HIV-1 attachment inhibitor1,2
EDUCATIONAL RESOURCES
View educational library for RUKOBIA, including videos and a downloadable resource
References:
- Ackerman P, Thompson M, Molina J M, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
- Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prod rug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):7 40-751.
FSTWCNT220002
